nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.12.2009 | Symposium in Writing

The importance of the age factor in cancer vaccination at older age

verfasst von: Claudia Gravekamp

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Cancer is an age-related disease, and with the graying of the society there is an increasing need to optimize cancer management and therapy to elderly patients. Vaccine therapy for cancer is less toxic than chemotherapy or radiation and could be, therefore, especially effective in older, more frail cancer patients. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to T cell unresponsiveness, a phenomenon also observed in cancer patients per se. Therefore, research is needed to establish whether age-specific tumor-immunological variables permit optimal use of cancer vaccines and therapy in the elderly. This review summarizes the current knowledge of T cell unresponsiveness in cancer patients and elderly, and the results of cancer vaccination in preclinical models at young and old age. Finally, new directions that may lead to effective cancer vaccination at older age will be proposed.

Gravekamp C, Bontenbal M, Ronteltap C et al (1990) In vitro and in vivo activation of CD4⁺ lymphocytes by autologous tumor cells. Int J Cancer 46:152–154CrossRef

Schreiber H (1998) Tumor immunology. In: Paul W (ed) Fundamental immunology, 4th edn. Lippencott-Raven, Philadelphia, pp 1237–1270

Gravekamp C (2001) Tailoring cancer vaccines to the elderly: the importance of suitable mouse models. MAD 122:1087–1105CrossRef

Koyama S, Maruyama T, Adachi S et al (1998) Expression of costimulatory molecules, B7-1 and B7-2 on human gastric carcinoma. J Can Res Clin Oncol 124:383–388CrossRef

Maurer CA, Friess H, Kretschmann B et al (1998) Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. Int J Cancer 79:76–81PubMedCrossRef

Loo DT, Chalupny NJ, Bajorath J et al (1997) Analysis of 4-IBBL and laminin binding to murine 4-IBB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-IBB. J Biol Chem 272:6448–6456PubMedCrossRef

Melero I, Shuford WW, Newby SA et al (1997) Monoclonal antibodies against the 4-IBB T cell activation molecule eradicate established tumors. Nat Med 3:682–685PubMedCrossRef

Garrido F, Ruiz-Cabello F, Cabrera T et al (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89–95PubMedCrossRef

Akbasak A, Oldfield EH, Saris SC (1991) Expression and modulation of major histocompatibility antigens on murine brain tumors in vitro. J Neurosurg 75:922–929PubMedCrossRef

10.

Pedrinaci S, Algarra I, Garcia LA et al (1999) Selective upregulation of MHC class I expression in metastatic colonies derived from tumor clones of a murine fibrosarcoma. Int J Clin Lab Res 29:166–173PubMedCrossRef

11.

Weber JS, Rosenberg SA (1990) Effects of murine tumor class I major histocompatibility complex expression on anti-tumor activity of tumor-infiltrating lymphocytes. J Natl Cancer Inst 82:755–761PubMedCrossRef

12.

Blieden TM, McAdam AJ, Foresman MD (1991) Class-I MHC expression in the mouse lung carcinoma, line 1: a model for class-I inducible tumors. Int J Cancer Suppl 6:82–89PubMedCrossRef

13.

Corver WE, Koopman LA, van der Aa J et al (2000) Four-color multiparameter DNA flow cytometry to study phenotypic intratumor heterogeneity in cervical cancer. Cytometry 39:96–107PubMedCrossRef

14.

Sypniewska RK, Hoflack L, Tarango M, Gauntt S, Leal BZ, Reddick RL, Gravekamp C (2005) Prevention of metastases with Mage-b vaccine in a mouse breast tumor model: potential for breast cancer therapy. Breast Cancer Res Treat 91:19–28PubMedCrossRef

15.

Zou W (2006) Regulatory T cell, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307PubMedCrossRef

16.

Curiel TJ (2007) Tregs and rethinking cancer immunotherapy. J Clin Investig 117:1167–1174PubMedCrossRef

17.

Bluestone JA, Abbas AK (2003) Natural versus adaptive regulatory T cells. Nat Rev Immunol 3:253–257PubMedCrossRef

18.

Shimizu J, Yamzaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD4+CD25+ T cells: a common basis between tumor immunityand autoimmunity. J Immunol 163:5211–5218PubMed

19.

Tanaka H, Tanaka J, Kjaergaard J et al (2002) Depletion of CD4+CD25+ regulatory T cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25:207–217PubMedCrossRef

20.

Chen A, Liu S, Park D et al (2007) Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adaptive T cell transfer. Cancer Res 67:1291–1298PubMedCrossRef

21.

Mahnke K, Schonfeld K, Fondel S et al (2007) Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 120:2723–2733PubMedCrossRef

22.

Van Elsas A, Hurwitz AA, Allison P (1999) Combination of immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-1) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 3:355–366CrossRef

23.

Maker AV, Attia P, Rosenberg SA (2005) Analysis of the cellular mechanism of anti-tumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175:7746–7754PubMed

24.

Gavin MA et al (2007) Foxp3-dependent programme of regulatory T-cell differentiation. Nat 445:771–775CrossRef

25.

Wan YY, Flavel RA (2007) Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445:766–770PubMedCrossRef

26.

Sakaguchi S, Sakaguchi N, Asano M et al (1995) Immunologic self-tolerance maintained by activated T cells express IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151–1164PubMed

27.

Gajewski TF, Meng Y, Harlin H (2006) Immune suppression in tumor microenvironment. J Immunother 29:233–240PubMedCrossRef

28.

Kobie JJ, Wu RS, Kurt RA et al (2003) Transforming growth factor beta inhibits the antigen-presenting functions and anti-tumor activity of dendritic cell vaccines. Cancer Res 63:1860–1864PubMed

29.

Chen ML, Pittet MJ, Gorelik L et al (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. PNAS 102:419–424PubMedCrossRef

30.

Park SJ, Nakagawa T, Kitamura H et al (2004) IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 173:3844–3854PubMed

31.

Jonuleit H, Schmitt E, Steinbrink K et al (2001) Dendritic cells as a tool to induce anergic and regulatory T-cells. Trends Immunol 22:394–400PubMedCrossRef

32.

Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B et al (2005) Tumor cyclooxygenase-2/prostaglandine E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Res 65:5211–5220PubMedCrossRef

33.

Kuroda E, Yamashita U (2003) Mechanisms of enhanced macrophage-mediated prostaglandine E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice. J Immunol 170:757–764PubMed

34.

Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 7:1027–1034CrossRef

35.

Hwu P, Du MX, Lapointe R et al (2000) Indolamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164:3596–3599PubMed

36.

Kim R, Manabu E, Tanabe E et al (2006) Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66:5527–5536PubMedCrossRef

37.

Sica A, Saccani A, Bottazzi B et al (2000) Autocrine production of IL-10 mediates defective IL-12 production and NFk-B activation in tumor-associated macrophages. J Immunol 164:762–767PubMed

38.

Starace D, Riccioli A, D’Alessio A et al (2004) Characterization of signaling pathways leading to Fas expression induced by TNFα: pivotal role of NF-κB. FASEB 19:473–475

39.

Shi W, Li L, Shi X et al (2006) Inhibition of nuclear factor-kB activation is essential for membrane-associated TNF-alpha-induced apoptosis in HL-60 cells. Immunol Cell Biol 84:366–373PubMedCrossRef

40.

Baron-Bodo V, Doceur P, Levebre ML et al (2005) Anti-tumor properties of human-activated macrophages produced in large scale for clinical application. Immunobiolog 210:267–277CrossRef

41.

Ouyang GF, Saio M, Suwa T et al (2006) Interleukin-2 augmented activation of tumor-associated macrophage plays the main role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro. Int J Oncol 28:1201–1208PubMed

42.

Miller RA (1996) The aging immune system: primer and prospectus. Science 273:70–74PubMedCrossRef

43.

Utsuyama M, Hirokawa K, Kurashima C et al (1992) Differential age-change in the number of CD4+CD45RA+ and CD4+CD29+ T cell subsets in human peripheral blood. Mech Ageing Dev 63:57–68PubMedCrossRef

44.

Grubeck-Loebenstein B (1997) Changes in the aging immune system. Biologicals 25:205–208PubMedCrossRef

45.

George AJT, Ritter MA (1996) Thymic involution with ageing: obsolescence or good houskeeping? Immunol Today 17:267–272PubMedCrossRef

46.

Tamir A, Eisenbraun MD, Garcia GG et al (2000) Age-dependent alterations in the assembly of signal transduction complexes at the site of T cell/APC interaction. J Immunol 165:1243–1251PubMed

47.

Wack A, Cossarizza A, Heltai S et al (1998) Age-related modifications of the human alphabeta T cell repertoire due to different clonal expansions in the CD4+ and CD8+ subsets. Int Immunol 10:1281–1288PubMedCrossRef

48.

Effros RB (2006) Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine 7:599–604

49.

Effros RB (2004) Replicative senescence of CD8 T cells: effect on human aging. Exp Ger 39:517–524CrossRef

50.

Filaci G, Fravega M, Negrini S et al (2004) Nonantigen-specific CD8+ suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T cell proliferation and CTL function. Hum Immunol 65:142–156PubMedCrossRef

51.

Nishioka T, Shimizu J, Yamazaki S et al (2006) CD4+CD25+Fox3+ T cells and CD4+CD25-Fox3+ T cells in aged mice. J Immunol 176:6586–6593PubMed

52.

Gregg R, Smith CM, Clark FJ et al (2005) The number of human peripheral blood CD4+CD25 high regulatory T cells increases with age. Clin Exp Immunol 140:540–546PubMedCrossRef

53.

McElhaney JE, Meneilly GS, Lechelt KE et al (1994) Split-virus influenza vaccines: do they provide adequate immunity in the elderly? Gerontol 49:M37–M43

54.

Quyang Q, Cicek G, Westendorp RGJ et al (2000) Reduced IFNγ production in elderly people following in vitro stimulation with influenza vaccine and endotoxin. Mech Ageing Dev 121:131–137

55.

Lung TL, Sauerwein-Teissl M, Parson W et al (2000) Unimpaired dendritic cells can be derived from monocytes in old age and can mobilize residual function in senescent T cells. Vaccine 18:1606–1612PubMedCrossRef

56.

Sauerwein-Teissl M, Schonitzer D, Grubeck-Loebenstin B (1998) Dendritic cell responsiveness to stimulation with influenza vaccine is unimpaired in old age. Exp Ger 33:625–631CrossRef

57.

Sprecher E, Becker Y, Kraal G et al (1990) Effect of aging on the epidermal dendritic cell population in C57Bl/6J mice. J Invest Dermatol 94:247–253PubMedCrossRef

58.

Sunderkotter C, Laden H, Luger TA (1997) Aging and the skin immune system. Arch Dermatolog 133:1256–1262CrossRef

59.

Bella D, Bierti L, Presicce P et al (2007) Peripheral blood dendritic cells and monocytes are differentially regulated in the elderly. Clin Immunol 122:220–228PubMedCrossRef

60.

Agrawal A, Agrawal S, Cao JN et al (2007) Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinisitide 3-kinase-signaling pathway. J Immunol 178:6912–6922PubMed

61.

Renshaw M, Rocjwell J, Engleman C et al (2002) Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol 169:4697–4701PubMed

62.

Muss HB (2001) Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status. J Natl Cancer Inst Monogram 30:52–55

63.

Provinciali M, Argentati K, Tibaldi A (2000) Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther 7:624–632PubMedCrossRef

64.

Provinciali M, Smorlesi A, Donnini A et al (2003) Low effectiveness of DNA vaccination against HER2/neu in aging. Vaccine 21:843–848PubMedCrossRef

65.

Lustgarten J, Dominguez AL, Thomas M (2004) Aged mice develop protective anti-tumor responses with appropriate costimulation. J Immunol 173:4510–4515PubMed

66.

Sharma S, Domiguez AL, Lustgarten J (2006) Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB. Exp Ger 41:78–84CrossRef

67.

Grolleau-Julius A, Abernathy L, Harning E, Yung RL (2008) Mechanisms of murine dendritic cell antitumor dysfunction in aging. Cancer Immunol Immunother. doi: 10.1007/s00262-008-0636-9

68.

Gravekamp C, Sypniewska R, Gauntt S, Tarango M, Price P, Reddick R (2004) Behaviour of metastatic and non-metastatic tumors in old mice. Exp Biol Med 229:665–675

69.

Gravekamp C, Leal B, Denny A, Bahar R, Lampkin S, Castro F, Moore D, Reddick R (2008) In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model, 4T1. Cancer Immunology and Immunotherapy. Cancer Immunol Immunother 57:1067–1077PubMedCrossRef

70.

Gravekamp C (2007) Cancer vaccines in old age. Exp Gerontol 42:441–450PubMedCrossRef

71.

Gravekamp C, Kim SH, Castro F (2008). Cancer vaccination: manipulation of immune responses at old age. Mech Ageing Dev (in press)

72.

Stacy S, Infante AJ, Wall K et al (2003) Recall immune memory: a new tool for generating late onset autoimmune myasthenia gravis. Mech Ageing Dev 124:931–940PubMedCrossRef

73.

Tan JT, Dudl E, LeRoy E et al (2001) IL-7 is critical for homeostatic proliferation and survival of naïve T cells. PNAS 98:8732–8737PubMedCrossRef

74.

Nardin A, Levebre ML, Labroquere K et al (2006) Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets 6:123–133PubMedCrossRef

75.

Kim SH, Castro F, Gonzalez D, Maciag P, Paterson Y, Gravekamp C (2008) Mage-b delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. Br J Cancer 99:741–749PubMedCrossRef

76.

Fest S, Heubener N, Weixler S et al (2006) Characterization of GD2 peptide miotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res 66:10567–10575PubMedCrossRef

77.

DeMatos P, Abdel-Wahab Z, Vervaert C, Seigler HF (1998) Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol 185:65–74PubMedCrossRef

78.

Niethammer AG, Xiang R, Becker JC et al (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8:1369–1375PubMedCrossRef

79.

Fang L, Lonsdorf AS, Hwang ST (2008) Immunotherapy for advanced melanoma. J Invest Dermatol 128:2596–2605PubMedCrossRef

80.

Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immuno therapy: moving beyond current vaccines. Nature Med 10:999–1015CrossRef

81.

Pardal R, Clarke MF, Morrison SJ (2003) Applying the principle of stem-cell biology to cancer. Nat Rev Cancer 3:895–902PubMedCrossRef

Titel: The importance of the age factor in cancer vaccination at older age
verfasst von: Claudia Gravekamp
Publikationsdatum: 01.12.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 12/2009
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-009-0683-x

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

The importance of the age factor in cancer vaccination at older age

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2009

Impact of aging on cancer immunity and immunotherapy

Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts

Downregulation of interleukin-7 and hepatocyte growth factor in the thymic microenvironment is associated with thymus involution in tumor-bearing mice

Cancer, aging and immunotherapy: lessons learned from animal models

Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53

Graft versus neuroblastoma reaction is efficiently elicited by allogeneic bone marrow transplantation through cytolytic activity in the absence of GVHD

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie